Peter Campochiaro MD
Professor of Ophthalmology
Professor of Ophthalmology
Khanani AM, Campochiaro PA, Graff JM, Marcus DM, Miller D, Mittra RA, Regillo C, Sheth VS, Bobbala A, Gune S, Lin S, Quezada-Ruiz C, Malhotra V (2025) Continuous ranibizumab via port delivery system vs monthly ranibizumab for treatment of diabetic macular edema: the Pagoda randomized clinical trial. JAMA Ophthalmol. 2025 Mar6:e250006. doi: 10.1001/jamaophthalmol.2025.0006. Online ahead of print. PMID: 40048197
Campochiaro PA, Eichenbaum D, Chang MA, Clark WL, Graff JM, Le Pogam S, Cavichini Cordeiro M, Gune S, Rabena M, Singh N, Lin S, Callaway N (2024) Interim results of the phase III Portal Extension Trial of the Port Delivery System with ranibizumab in neovascular age-related macular degeneration Ophthalmol Retina. 2025 Feb;9(2):144-155. doi: 10.1016/j.oret.2024.05.021. Epub 2024 Aug 30. PMID: 39209113
Campochiaro PA, Avery R, Brown DM, Heier JS, Ho AC, Huddleston SM, Jaffe GJ,Khanani AM, Pakola S, Pieramici DJ, Wykoff CC, Van Everen S (2024). Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. Lancet 2024 Apr 20;403(10436):1563-1573. doi: 10.1016/S0140-6736(24)00310-6.
Shen J, Lima e Silva R, Zhang M, Luly KM, Hackett SF, Tzeng SY, Lowmaster, SM, Shannon SR, Wilson DR, Green JJ, Campochiaro PA (2024) Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes. Sci Adv. 2024 Mar 8;10(10):eadl3576. doi: 10.1126/sciadv.adl3576.
Kanan Y, Hackett SF, Hsueh HT, Khan M, Ensign LM, Campochiaro PA (2023) Reduced inspired oxygen decreases retinal superoxide radicals and promotes cone function and survival in a model of retinitis pigmentosa. Free Radic Biol Med 198:118-122.
Kanan Y, Hackett SF, Taneja K, Khan M, Campochiaro PA (2022). Oxidative stress- induced alterations in retinal glucose metabolism in retinitis pigmentosa. Free Radic Biol Med 181:143-153.
Shen J, Kim J, Tzeng SY, Ding K, Hafiz Z, Long D, Wang J, Green JJ, Campochiaro PA (2020). Suprachoroidal gene transfer with nonviral nanoparticles. Sci Adv 6(27):eaba1606. doi: 10.1126/sciadv.aba1606. PMID:32937452 PMCID:PMC7458446
Campochiaro PA, Iftikhar M, Hafiz G, Akhlaq A, Tsai G, Wehling D, Lu L, Wall GM, Singh MS, Kong X (2020). Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. J Clin Invest 130:1527-1541.
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, Chiang Y, Ehrlich JS, Erickson S, Hanley WD, Horvath J, Maass KF, Singh N, Tang F, Barteselli G. Ophthalmology. 2019 Apr 1. pii: S0161-6420(18)33328-1. doi: 10.1016/j.ophtha.2019.03.036. PMID: 30946888
Metipranolol promotes structure and function of retinal photoreceptors in the rd10 mouse model of human retinitis pigmentosa. Kanan Y, Khan M, Lorenc VE, Long D, Chadha R, Sciamanna J, Green K, Campochiaro PA. J Neurochem. 2019 Jan;148(2):307-318. doi: 10.1111/jnc.14613. Epub 2018 Dec 3. PMID: 30315650
Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection. Zhang Y, Bazzazi H, Lima E Silva R, Pandey NB, Green JJ, Campochiaro PA, Popel AS. Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5266-5276. doi: 10.1167/iovs.17-23632. PMID: 30383198
AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration. Liu Y, Fortmann SD, Shen J, Wielechowski E, Tretiakova A, Yoo S, Kozarsky K, Wang J, Wilson JM, Campochiaro PA. Mol Ther. 2018 Feb 7;26(2):542-549. doi: 10.1016/j.ymthe.2017.12.002. Epub 2017 Dec 8. PMID: 29292162
Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA. Lancet. 2017 Jul 1;390(10089):50-61. doi: 10.1016/S0140-6736(17)30979-0. Epub 2017 May 17. Erratum in: Lancet. 2017 Jul 1;390(10089):28. PMID: 28526489
The Nicotinic Cholinergic Pathway Contributes to Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity. Hackett SF, Seidel C, Abraham S, Chadha R, Fortmann SD, Campochiaro PA, Cooke JP. Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):1296-1303. doi: 10.1167/iovs.16-20670. PMID: 28241318
Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. Silva RLE, Kanan Y, Mirando AC, Kim J, Shmueli RB, Lorenc VE, Fortmann SD, Sciamanna J, Pandey NB, Green JJ, Popel AS, Campochiaro PA. Sci Transl Med. 2017 Jan 18;9(373). pii: eaai8030. doi: 10.1126/scitranslmed.aai8030. PMID: 28100839
The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization. Zeng M, Shen J, Liu Y, Lu LY, Ding K, Fortmann SD, Khan M, Wang J, Hackett SF, Semenza GL, Campochiaro PA. J Mol Med (Berl). 2017 Apr;95(4):417-429. doi: 10.1007/s00109-016-1498-9. Epub 2016 Dec 21. PMID: 28004126
Sustained delivery of a HIF-1 antagonist for ocular neovascularization. Iwase T, Fu J, Yoshida T, Muramatsu D, Miki A, Hashida N, Lu L, Oveson B, Lima e Silva R, Seidel C, Yang M, Connelly S, Shen J, Han B, Wu M, Semenza GL, Hanes J, Campochiaro PA. J Control Release. 2013 Dec 28;172(3):625-33. doi: 10.1016/j.jconrel.2013.10.008. Epub 2013 Oct 12. PMID: 24126220
Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, Kim J, Popel AS, Campochiaro PA, Green JJ. Biomaterials. 2013 Oct;34(30):7544-51. doi: 10.1016/j.biomaterials.2013.06.044. Epub 2013 Jul 10. PMID: 23849876